722 related articles for article (PubMed ID: 31838290)
21. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
[TBL] [Abstract][Full Text] [Related]
22. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
[TBL] [Abstract][Full Text] [Related]
23. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
24. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
25. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
27. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
28. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
29. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
[TBL] [Abstract][Full Text] [Related]
31. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
33. Compounds Consisting of Quinazoline, Ibuprofen, and Amino Acids with Cytotoxic and Anti-Inflammatory Effects.
Garduño-Villavicencio LR; Martínez-Ortega U; Ortiz-Sánchez E; Tinajero-Rodríguez JM; Hernández-Luis F
ChemMedChem; 2024 May; 19(10):e202300651. PubMed ID: 38354370
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
Tu Y; OuYang Y; Xu S; Zhu Y; Li G; Sun C; Zheng P; Zhu W
Bioorg Med Chem; 2016 Apr; 24(7):1495-503. PubMed ID: 26906472
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
